BRANFORD, Conn., Nov. 18, 2021 /PRNewswire/ -- IsoPlexis
Corporation (NASDAQ: ISO), the leader in functional
single-cell proteomics, today announced the publication of two
high-impact clinical research studies in Nature Medicine.
Both papers demonstrate the unique utility of IsoPlexis'
single-cell proteomic platform for predicting the potency of novel
cell therapies, including chimeric antigen receptor (CAR) T cells
in blood cancer and tumor infiltrating lymphocytes (TILs) against
solid tumors.
![(PRNewsfoto/IsoPlexis) (PRNewsfoto/IsoPlexis)](https://mma.prnewswire.com/media/886890/isoplexis__Logo.jpg)
In addition, IsoPlexis has broadened its "functional cell
library" of available workflows to cover vastly more engineered
cell types to meet needs in the rapidly expanding cell therapy
space. Other than autologous and allogeneic CAR-T cells and TILs,
these include natural killer (NK) cells, T-cell receptor
transgenic T cells (TCR-T), and various types of monocytes. The
continued expansion of this library of proteomically-driven single
cells provides the ability to characterize a comprehensive range of
cell therapy product types to propel the fast-moving cell therapy
industry.
"One of the greatest challenges in improving cell therapies is
understanding exactly how these living immune drugs work, as early
as possible. Through these two high-impact publications, the
researchers leveraged our unique single-cell proteomic analysis to
gain a better understanding of how CAR-Ts and TILs function, which
then led to improved assessments of quality, potency, and
durability," said Sean Mackay, CEO
and co-founder of IsoPlexis.
Data from the company's single-cell functional proteomics
platform was published in Nature Medicine by
researchers from Stanford University.
The paper, titled "CAR T cells with dual targeting of CD19 and CD22
in adult patients with recurrent or refractory B cell malignancies:
a phase 1 trial," identifies early indicators of response or
relapse in CAR-T therapy, leveraging IsoPlexis' platform. The
researchers found that functional protein production from single
cells is a meaningful attribute to predict the potency of CAR-T
cell therapies. "Our results suggest that engineering iterations
should be guided by careful studies of single-cell CAR
polyfunctionality incorporating cytokine production as a critical
quality attribute."
In another Nature Medicine paper titled
"Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant
metastatic lung cancer: a phase 1 trial", researchers from
Duke University and Moffit Cancer
Center published data on treatment response and potency in TIL
therapy using IsoPlexis' single-cell functional proteomics
platform. The platform's functional readouts were shown to be
critical for understanding patient response to the novel TIL
therapies. "We assessed the polyfunctional strength index (PSI),
which is an indicator of the number of cells capable of secreting
multiple types of cytokines. As PSI reflects the ability of a T
cell to carry out multiple functions, it is recognized as a metric
for the potency of cell therapy and for the efficacy of
vaccines."
Visit our publications page to see the wide range of use cases
for single-cell proteomics in accelerating a variety of cell
therapies in high impact publications.
About IsoPlexis
IsoPlexis is leading a new era of functional proteomics. By
identifying our most proteomically active single cells (or
"superhero cells") for the first time, IsoPlexis enables
researchers to connect more directly to in vivo biology and develop
more precise and personalized therapies. IsoPlexis has been named
Top Innovation or Design by The Scientist Magazine, Fierce, BIG
Innovation, Red Dot and multiple others. The IsoPlexis platform is
used globally by researchers, including those at the top 15 global
pharmaceutical companies and at the majority of leading U.S.
comprehensive cancer centers.
Cautionary Note Regarding Forward Looking Statements
Certain statements in this press release are forward-looking
statements that are subject to risks and uncertainties that could
cause results to be materially different than expectations.
Important factors that could cause actual results to differ
materially include: the rate of adoption of the Company's
technology by its customers and potential customers as well as the
risk factors set forth in the Risk Factors section of the Company's
prospectus filed with the SEC. These forward-looking
statements are not guarantees of future performance and speak only
as of the date hereof, and, except as required by law, IsoPlexis
disclaims any obligation to update these forward-looking statements
to reflect future events or circumstances.
Investor Contact
investors@isoplexis.com
Press Contact
press@isoplexis.com
Related Links
www.isoplexis.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/isoplexis-expanded-cell-therapy-offerings-demonstrated-in-nature-medicine-publications-301427727.html
SOURCE IsoPlexis